Source document
Settlement Agreement between the United States, GlaxoSmithKline LLC and relators (off-label promotion civil settlement, 2012)
Has everything in it been taken?
CompleteReviewed 8 Oct 2026
Reviewed. Everything in it that belongs in the tables has been taken.
What the document holds
Scanned settlement agreement (34 pp., read by OCR) between the United States, relators and GlaxoSmithKline LLC resolving four qui tam actions in D. Mass. (ex rel. Thorpe; ex rel. Gerahty; ex rel. Graydon; ex rel. LaFauci): covered conduct (off-label promotion and kickbacks for Paxil, Wellbutrin, Advair, Lamictal, Zofran; kickbacks for Imitrex, Lotronex, Flovent, Valtrex); settlement amount $1,042,612,800 plus 1.625% interest from 1 Dec 2011, allocated by drug (adds up to the total), split federal $832,485,436 / Medicaid participating states $210,127,364; releases, excluded claims, unallowable costs, dismissal terms; the relators' share under 3730(d) is expressly left open; signature pages (DOJ, HHS-OIG, TRICARE, OPM, GSK, relators Thorpe, Hamrick, Gerahty, Burke, Graydon, LaFauci and counsel). Nothing from it was in the data. Added: 1 case (allocation by drug in its notes).
What it supports
1 row on this site come from this document. Each one opens with the page and the exact words.
About the document
What it covers GSK off-label civil settlement terms
Notes Scanned; read by OCR. It explicitly leaves the relators' share open ('This agreement does not cover the claims of any Relator to a share of the proceeds ... under 31 U.S.C. § 3730(d)'), so it cannot give the relator share. The Avandia and nominal-pricing agreements (same DOJ page) were also checked and do not state shares.
Source id usa-doj-gsk-offlabel-settlement-2012 · accessed 5 Oct 2026